Turati F, et al (2011). A meta-analysis of coffee consumption and pancreatic cancer, Annals of Oncology, published online ahead of print. DOI: 10.1093/annonc/mdr3

Print this page

Background

Since when in 1981 a case–control study showed a positive association between coffee and pancreatic cancer, several studies reported inconsistent results on this issue.

Materials and methods

We conducted a systematic bibliography search updated March 2011 to identify observational studies providing quantitative estimates for pancreatic cancer risk in relation to coffee consumption. We used a meta-analytic approach to estimate overall relative risk (RR) and 95% confidence interval (CI) for the highest versus the lowest coffee consumption categories, using random-effects models.

Results

Based on 37 case–control and 17 cohort studies (10 594 cases), the pooled RR for the highest versus lowest intake was 1.13 (95% CI 0.99–1.29). Considering only the smoking-adjusting studies, the pooled RRs were 1.10 (95% CI 0.92–1.31) for the 22 case–control, 1.04 (95% CI 0.80–1.36) for the 15 cohort, and 1.08 (95% CI 0.94–1.25) for all studies. The pooled RR for the increment of one cup of coffee per day was 1.03 (95% CI 0.99–1.06) for the 28 smoking-adjusting studies reporting three or more coffee consumption categories. No significant heterogeneity was observed across strata of study design, sex, geographic region, and other selected characteristics.

Conclusions

This meta-analysis provides quantitative evidence that coffee consumption is not appreciably related to pancreatic cancer risk, even at high intakes.

 

This information is intended for Healthcare professional audiences.
Please consider the environment before printing.